Gene or Genome – Page 6

Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials

3 months ago talkbio0Tagged Antibodies, Clinical Trials, DKK1 gene, LEAP, Malignant neoplasm of stomach, Performance

Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance

Trump 2.0: RFK Confirmation Hearings and Ongoing Clinical Trials Amidst Administrative Changes

3 months ago talkbio0Tagged Clinical Trials, Confirmation, Hearings, NIH Mouse, Partnership, Policy, RFK gene, Transplant Registry Unified Management Program

Trump 2.0, RFK Confirmation Hearings, Clinical Trials, NIH Grant Reviews, US-India Partnership, Second Term Policies

Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges

3 months ago talkbio0Tagged Achondroplasia, BioMarin, BridgeBio, CNP gene, Disorder of skeletal system, Dwarfism, genetic bone disorders, infigratinib, RBM-007, TransCon, Voxzogo

Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.

Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

3 months ago talkbio0Tagged Biosciences, EU, Inhibitor, Junshi, Loqtorzi, Nasopharyngeal carcinoma, PDCD1 gene, Pharma, rights

Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts

Novartis Secures Temporary Block on Generic Version of Entresto

3 months ago talkbio0Tagged Entresto, generic version, Heart failure, MSN gene, Novartis, Obstruction, Transitory

Novartis, Entresto, generic version, MSN Pharmaceuticals, temporary block, heart failure drug

AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma

3 months ago talkbio0Tagged acalabrutinib, Approved, AstraZeneca, BTK gene, Calquence, first-line, Inhibitor, Mantle cell lymphoma, United States Food and Drug Administration

AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval

Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges

3 months ago talkbio0Tagged 2025, Biopharma, business career, CDMO, Charles, constraints, Drug Industry, IL31RA gene, revenue outlook, River Laboratories, spending, trends qualifier

Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends

GE HealthCare and UCSF Collaborate on Innovative Imaging Solutions for Cancer and Neurodegenerative Diseases

3 months ago talkbio0Tagged brain health, Cancer Imaging, ELAVL2 gene, GE HealthCare, innovation, Joint Research Program, Neoplasms, Neurodegenerative Disease Imaging, Precision - temporal, UCSF

GE HealthCare, UCSF, Cancer Imaging, Neurodegenerative Disease Imaging, Precision Oncology, Brain Health, Joint Research Program, Care Innovation Hub

GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases

3 months ago talkbio0Tagged Automated (qualifier value), brain health, ELAVL2 gene, GE HealthCare, innovation, Magnetic Resonance Imaging, Medical Imaging, Neoplasms, Neurodegenerative Disorders, Precision - temporal, radiopharmaceutical therapies, UCSF

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.

Tune Therapeutics Secures $175M in Series B Funding to Advance Epigenome Editing Programs

3 months ago talkbio0Tagged biotech, Epigenome, gene therapy, Hepatitis B treatment, Investments, Series B, Tune

Epigenome editing, Tune Therapeutics, Series B funding, Hepatitis B treatment, Gene therapy, Biotech investment